Viewing profile — predxionbio

There’s a lot of really interesting work left to be done in this area. In our company’s other life we’re involved in CAR-T research, which involves exploiting natural pathways in o…

I think we're up against many of the same challenges everyone else (Roche, Abbott, et al.) is up against. At the end of the day if we could all wave a magic wand and fix supply cha…

I agree that reliable antibody tests will be a help to policymakers in how they model the continued stay-at-home posture and begin to open things back up. I think the jury is still…

Good sleuthing! As you suspect we functionalize the our sensor surface to specifically bind the virus. We've partnered with a therapeutics company developing highly specific monocl…

Couple of things at play here. First is we are developing a non-PCR based viral detection test. Many of the molecular tests approved rely on many of the same ancillary components (…

Hi there. We are developing a saliva (e.g., spit in tube) type test. There are a couple of reasons for this including: - supply chain issues with flocked nasal swabs and viral tran…

I'm not familiar with the acronym PSM. Can you expand? Are you familiar with the work of Dr. Chui at UCSF? His group has done some really cool work using mNGS to detect/diagnose em…

Test complexity (sample prep, test workflow) is a real challenge to achieving testing scales at orders of magnitude above what is presently available. We should hopefully have bori…

A regular ELISA/immunoassay is: surface->Ab->protein Sounds like your undergrad kid has been paying attention in class...

Great question. This is one of the implementations we're actually developing. One of the challenges with the implementation of testing on this scale is not necessarily on the techn…

Hi, Walker here, one of the PreDxion Bio co-founders. Heres a some more information on the technology underlying the test we are developing: https://pubmed.ncbi.nlm.nih.gov/2579083…

Hi, Walker here, one of the PreDxion co-founders. Up until recently we've been focused on developing our technogy as a point of care biosensor for us in patients experiencing dysfu…

0) From a clinical perspective this is data we are generating on an on going basis. Analytically this is a largely a function of the characteristics of the affinity, specificity of…